DSM Sinochem Pharmaceuticals to be bought by Bain Capital

| By | Drug Development, Drug Manufacturing, Pharmaceutical Deal

Bain Capital Private Equity, a leading global private investment firm, announced that it has signed a definitive agreement to acquire DSM Sinochem Pharmaceuticals (DSP), the global leader in sustainable antibiotics, next-generation statins and anti-fungals.

DSP is a 50/50 Joint Venture of Royal DSM, a global science-based company in Nutrition, Health and Sustainable Living, and Sinochem Group, a Fortune 500 enterprise.

With roots that date back to 1869, and a long history of technical innovation, DSP is the leading company in beta-lactam antibiotics, and also provides next-generation statins and anti-fungals. In 2017, the company generated sales of approximately €440 million.

Headquartered in Singapore, the group has manufacturing sites and sales offices in China, India, the Netherlands, Spain, the USA and Mexico.

The transaction is expected to be completed in the fourth quarter of 2018, subject to customary regulatory approvals and consultations.

SOURCE: bain capital
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.